GENERAL INFORMATION
Established:  1995
Ownership:  Private

Core business

Products for research labs and clinical diagnostics centers.

Employees:  55
Market regions:  France, Italy, Japan, USA
Main Markets:  Medical devices companies. Clinical laboratories.

Overview

NOVAMED LTD. is a privately owned Israeli life science company
founded in December 1995. Since its inception NOVAMED has been
committed to the development of innovative, proprietary
diagnostic systems with worldwide marketing potential.

NOVAMED has become an important player in selected markets by
combining user need for a particular application with a
cost-effective product. Such products include the patented and
FDA approved DipStreak and ChromoStreak devices for diagnosis of
urinary tract infections and NovaStreak for detection of
microorganisms present in food and dairy products. NOVAMED's
rapid one-step diagnostic assays for viral infections
(AdenoStick, RotaStick and CombiStick) are all the latest third
generation products. NOVAMED's Uni-Sep and Uni-Sorb line of
products have modernized procedures for lymphocyte isolation and
separation.

All NOVAMED's products are performance tested in a stringent
quality control program, according to ISO-9002 standards.
NOVAMED's unique corporate structure enables the company to be
both well established with a proven record of success in
production, sales and support, while allowing it to be an
aggressive "start-up" in regards to development of new products
and methodologies.

MDR TESTS Division is developing an assay kit to determine the
efficiency of an anti-cancer drug administered in combination
with an agent that will reverse (block) resistance to the drug.
To this were added new projects to exploit the Human Genome
Project in order to develop methods for identifying unique
peptides in cancer cells or pathogenic microorganisms.
With this information the clinician could know before starting
chemotherapy whether the treatment chosen is the best one.